N@N

SemBioSys to be featured on CBC/Radio-Canada documentary

_{//health-fitness.news-articles.net/content/2009/ .. be-featured-on-cbc-radio-canada-documentary.html}
^{Published in Health and Fitness on Friday, October 16th 2009 at 11:04 GMT by Market Wire}  

TSX symbol: SBS

CALGARY, Oct. 16 /CNW/ - SemBioSys Genetics Inc. (TSX:SBS) today announced that it will be featured in the Scientific Discovery Program "Découverte" on CBC National Television/Radio-Canada Télévision. The documentary, airing on CBC's French network on Sunday October 18th 2009 at 6:30 pm EDT, will describe SemBioSys' safflower-derived Biosimilar Insulin (SBS-1000) program. The documentary will be preceded by a short interview broadcasted on the national radio show "La Semaine Verte" on Sunday morning (Oct 18th). The story will also be aired on national news sometime between October 16th and 18th inclusively.

"Découverte" is the premier science and technology program presented by Radio-Canada in French and hosted by Charles Tisseyre. The documentary features award-winning journalist Marie-Claude Guay. After the program has aired, a video of the show will be available on the Radio-Canada website for "Découverte" at [ http://www.radio-canada.ca/emissions/decouverte/2009-2010/ ].

About SemBioSys

Calgary, Alberta-based SemBioSys is focused on leveraging our unique proprietary platform to manufacture high-value proteins and oils. SemBioSys' seed-based protein production system can provide for its partners product enablement, exceptionally low cost and unprecedented scalability. SemBioSys is applying the platform with high selectivity to products with tremendous clinical promise and value potential. The Company's current pharmaceutical development programs include insulin (SBS-1000, regulated as a biosimilar in Europe) and Apo AIMilano, a next-generation cardiovascular therapy. SemBioSys is listed on the Toronto Stock Exchange under the ticker SBS. More information is available at [ www.sembiosys.com ].

This press release contains certain forward-looking statements, including, without limitation, statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and other similar expressions which constitute "forward-looking information" within the meaning of applicable securities laws. Forward-looking statements reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, changing market conditions and market size, the acceptance of an IND by the FDA in respect of clinical studies, the submission of a CTA to the appropriate European authorities, the successful initiation and timely and successful completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time-to-time in the Company's ongoing filings with the Canadian securities regulatory authorities which filings can be found at [ www.sedar.com ]. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable Canadian securities laws.